Meibomian gland dysfunction (MGD) is the major cause of evaporative dry eye disease (EDED ... changes that are detected in human subjects. Atrophic glands also showed evidence of epithelial ...

For treatment, injections deliver a monoclonal antibody to stop the growth of the blood vessels. The hope is that this allows ...

Until recently, treatments for vulvovaginal atrophy were limited to often insufficient or inappropriate oral estrogen therapies and over-the-counter lubricants and moisturizers. Currently ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has dosed its first patient in a clinical trial for its innovative ...

In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

Biotech player PYC Therapeutics (ASX:PYC) has dosed its first patient in a clinical trial seeking to ameliorate symptoms of ...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today reported financial results for ...

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease. iView Therapeutics completes enrollment in phase 1/2 trial for ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. Investigator ...